David M. Langenau

Affiliations: 
Molecular Pathology Massachusetts General Hospital & Harvard Medical School, Boston, MA, United States 
Google:
"David Langenau"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Prajapati K, Yan C, Yang Q, et al. (2024) The FLRT3-UNC5B checkpoint pathway inhibits T cell-based cancer immunotherapies. Science Advances. 10: eadj4698
Cardoso BA, Duque M, Gírio A, et al. (2023) CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia. Haematologica
Wei Y, Qin Q, Yan C, et al. (2022) Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma. Nature Cancer
Oliveira ML, Veloso A, Garcia EG, et al. (2022) Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia. Leukemia. 36: 1533-1540
Laukkanen S, Bacquelaine Veloso A, Yan C, et al. (2022) Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia. Blood
Zhang S, Yan C, Millar DG, et al. (2021) Antibody-peptide epitope conjugates for personalized cancer therapy. Cancer Research
Yan C, Yang Q, Zhang S, et al. (2021) Single-cell imaging of T cell immunotherapy responses in vivo. The Journal of Experimental Medicine. 218
Loontiens S, Dolens AC, Strubbe S, et al. (2020) PHF6 Expression Levels Impact Human Hematopoietic Stem Cell Differentiation. Frontiers in Cell and Developmental Biology. 8: 599472
Yan C, Do D, Yang Q, et al. (2020) Single-cell imaging of human cancer xenografts using adult immunodeficient zebrafish. Nature Protocols
Garcia EG, Veloso A, Oliveira ML, et al. (2020) PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. Leukemia
See more...